Lexicon Pharmaceuticals (LXRX) Shares Outstanding (Diluted Average) (2017 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $400.2 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $400.2 million, up 10.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $400.2 million (up 10.54% YoY), and the FY2025 annual result was $363.1 million, up 13.44% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $400.2 million in Q1 2026 per LXRX's latest filing, from $363.1 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $400.2 million in Q1 2026 and troughed at $165.7 million in Q4 2022.
• A 5-year average of $283.3 million and a median of $278.1 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) surged 47.59% in 2024, then increased 0.4% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $165.7 million in 2022, then soared by 33.43% to $221.1 million in 2023, then surged by 44.73% to $320.0 million in 2024, then climbed by 13.44% to $363.1 million in 2025, then increased by 10.24% to $400.2 million in 2026.
• Business Quant data shows LXRX's Shares Outstanding (Diluted Average) at $400.2 million in Q1 2026, $363.1 million in Q4 2025, and $362.9 million in Q3 2025.